Shares of CVS Health Corp (NYSE:CVS) have been given a consensus rating of “Buy” by the twenty-four analysts that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation, twelve have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $86.63.
Several brokerages have recently commented on CVS. ValuEngine lowered shares of CVS Health from a “buy” rating to a “hold” rating in a report on Sunday, December 31st. Vetr lowered shares of CVS Health from a “buy” rating to a “hold” rating and set a $77.11 price objective on the stock. in a report on Thursday, January 4th. SunTrust Banks upped their price objective on shares of CVS Health to $90.00 and gave the stock a “buy” rating in a report on Friday, January 5th. Morgan Stanley upgraded shares of CVS Health from an “equal weight” rating to an “overweight” rating and set a $88.00 price objective on the stock in a report on Friday, January 5th. Finally, Robert W. Baird set a $77.00 price objective on shares of CVS Health and gave the stock a “hold” rating in a report on Monday, December 4th.
In related news, EVP Helena Foulkes sold 19,965 shares of the stock in a transaction on Friday, February 16th. The shares were sold at an average price of $71.04, for a total value of $1,418,313.60. Following the transaction, the executive vice president now directly owns 65,072 shares of the company’s stock, valued at approximately $4,622,714.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.61% of the company’s stock.
Large investors have recently modified their holdings of the stock. FIL Ltd boosted its stake in CVS Health by 13.8% during the 2nd quarter. FIL Ltd now owns 514,836 shares of the pharmacy operator’s stock worth $41,424,000 after purchasing an additional 62,318 shares during the period. ETRADE Capital Management LLC lifted its stake in shares of CVS Health by 3.7% in the 2nd quarter. ETRADE Capital Management LLC now owns 55,653 shares of the pharmacy operator’s stock worth $4,478,000 after acquiring an additional 1,979 shares during the period. Ally Financial Inc. lifted its stake in shares of CVS Health by 20.0% in the 2nd quarter. Ally Financial Inc. now owns 90,000 shares of the pharmacy operator’s stock worth $7,241,000 after acquiring an additional 15,000 shares during the period. Livforsakringsbolaget Skandia Omsesidigt lifted its stake in shares of CVS Health by 17.9% in the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 77,859 shares of the pharmacy operator’s stock worth $5,645,000 after acquiring an additional 11,800 shares during the period. Finally, Checchi Capital Advisers LLC lifted its stake in shares of CVS Health by 14.5% in the 4th quarter. Checchi Capital Advisers LLC now owns 9,063 shares of the pharmacy operator’s stock worth $657,000 after acquiring an additional 1,150 shares during the period. Hedge funds and other institutional investors own 83.96% of the company’s stock.
CVS Health (CVS) traded up $0.03 during trading hours on Friday, reaching $62.45. 3,572,094 shares of the company’s stock traded hands, compared to its average volume of 8,764,878. The company has a quick ratio of 0.52, a current ratio of 1.02 and a debt-to-equity ratio of 0.59. The firm has a market cap of $63,854.64, a price-to-earnings ratio of 9.67, a price-to-earnings-growth ratio of 1.04 and a beta of 1.03. CVS Health has a 12 month low of $61.87 and a 12 month high of $84.00.
CVS Health (NYSE:CVS) last posted its earnings results on Thursday, February 8th. The pharmacy operator reported $1.92 earnings per share for the quarter, beating the consensus estimate of $1.88 by $0.04. The company had revenue of $48.39 billion for the quarter, compared to analyst estimates of $47.54 billion. CVS Health had a net margin of 3.58% and a return on equity of 17.21%. CVS Health’s revenue was up 5.3% on a year-over-year basis. During the same period in the previous year, the business posted $1.71 EPS. sell-side analysts anticipate that CVS Health will post 6.37 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, May 3rd. Investors of record on Monday, April 23rd will be given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 3.20%. The ex-dividend date of this dividend is Friday, April 20th. CVS Health’s dividend payout ratio (DPR) is 30.91%.
ILLEGAL ACTIVITY WARNING: “CVS Health Corp (CVS) Receives Average Recommendation of “Buy” from Brokerages” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/03/22/cvs-health-corp-cvs-receives-average-recommendation-of-buy-from-brokerages.html.
CVS Health Company Profile
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.